 |
|
|
| |
Treatment with Telaprevir-based Therapy after Exposure to Peg-IFN/RBV in the REALIZE Study: Results from the Phase IIIb C219 Rollover Study
|
| |
| |
Reported by Jules Levin
EASL April 24-28 Amsterdam 2013
Philippe Mathurin,1 Christoph Sarrazin,2 Henk W Reesink,3 Ola Weiland,4 Moises Diago,5 Geoffrey Dusheiko,6 Antonio Ascione,7 Ziv Ben-Ari,8 Andre Lyra,9 William Sievert,10 Michael Gschwantler,11 Tarek I Hassanien,12 Ewa Janczewska,13 Katrien Janssen,14 Don Luo,15 Anne Ghys,14 Sandra De Meyer,14 Gaston Picchio,15 Katrien de Backer,14 James Witek15
1Service Maladie de l'appareil digestif and INSERM U995, Université Lille 2, Lille, France; 2Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 3Academic Medical Center, Amsterdam, The Netherlands; 4Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden; 5Hospital General de Valencia, Valencia, Spain; 6Royal Free Hospital, London, UK; 7Centre for Liver Disease, Fatebenefratelli Hospital, Napoli, Italy; 8Sheba Medical Center, Tel Hashomer, Israel; 9Hospital São Rafael, Gastro-Hepatology, São Marcos, Brazil; 10Monash Medical Centre and Monash University, Melbourne, Australia; 11Wilhelminenspital, Vienna, Austria; 12University of California, San Diego, School of Medicine, La Jolla, CA, USA; 13Outpatients Clinic for Hepatology, Myslowice, Poland; 14Janssen Infectious Diseases, Beerse, Belgium; 15Janssen Research & Development LLC, NJ, USA
|
| |
|
|
|
|
|
